Newswise — September 12, 2022 – For high-risk patients with prostate cancer, treatment with novel hormonal agents (NHAs) followed by surgery can reduce the risk of recurrent and progressive cancer, compared to initial treatment with surgery, suggests a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
"Neoadjuvant therapy with NHAs before radical prostatectomy is an innovative approach to treatment of prostate cancer with high-risk characteristics," comments senior author Mary-Ellen Taplin, MD, of Dana-Farber Cancer Institute, Boston. "While we await the results of definitive clinical trials, our findings suggest that this approach can improve key outcomes, compared to starting treatment with radical prostatectomy." The study was led by Praful Ravi, MB, BChir, also of Dana-Farber.
Promising outcomes of neoadjuvant NHAs for high-risk prostate cancer
About 20% of patients with localized prostate cancers have characteristics placing them at high risk of cancer recurrence and progression. Even after treatment with surgery, radiation, and standard hormonal therapy, men with these high-risk prostate cancers (HRPCs) are more likely to have unfavorable outcomes. About half of patients with HRPC will have biochemical recurrence (BCR), based on rising prostate-specific antigen levels. About two-thirds of deaths from prostate cancer occur in men with HRPCs.
Recent studies have evaluated the use of NHAs as initial (neoadjuvant) therapy for HRPC, with the goal of shrinking the tumor before prostate cancer surgery (radical prostatectomy, or RP). A clinical trial is underway to compare the outcomes of neoadjuvant NHA versus standard hormone therapy. However, it won't answer the question of whether neoadjuvant NHA therapy followed by RP can improve outcomes, compared to initial RP.
To address this issue, Dr. Taplin and colleagues compared outcomes in two groups of patients with HRPC. One group included 259 men with HRPC treated from 2010 to 2016, who underwent RP without any neoadjuvant therapy. The other group consisted of 112 men who received neoadjuvant therapy with NHAs before surgery (neo-RP). The main outcomes of interest were BCR and survival without cancer progression (metastasis-free survival). The analysis included adjustment (inverse probability of treatment weighting) to minimize differences in characteristics between groups.
After neoadjuvant therapy, 12% of men in the neo-RP group were classified as having minimal residual disease: in other words, the prostate cancer was almost completely eliminated after treatment with NHAs. Patients undergoing neo-RP were also more likely to have negative margins after RP, indicating no evidence of cancer after surgery.
Key follow-up outcomes were also better after neo-RP. On adjusted analysis, 59% of men receiving NHAs before surgery were free of BCR at 3 years' follow-up, compared to 15% of those undergoing RP without neoadjuvant therapy. There was a similar improvement in rates of metastasis-free survival. Ninety-six percent of men in the neo-RP group were alive without evidence of tumor spread after 3 years, compared to 68% in the RP group.
Men in the neo-RP group were also less likely to need further treatment, including adjuvant therapy (7% versus 24%) or salvage therapy (34% versus 46%). With current follow-up of about 6 years, overall survival rate was not significantly different between groups.
The researchers note some limitations of their study – particularly the inability to account for other confounding factors that might have contributed to differences in outcomes between groups. However, "the results suggest significant benefit with [NHA prior to RP] in unselected patients with HRPC," Drs. Ravi and Taplin and coauthors conclude. They emphasize the need to confirm the benefits of the neo-RP approach in ongoing randomized trials.
DOI: 10.1097/JU.0000000000002803
###
About The Journal of Urology®
The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.
About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,800 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
RSS